JP2011516410A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516410A5 JP2011516410A5 JP2010548040A JP2010548040A JP2011516410A5 JP 2011516410 A5 JP2011516410 A5 JP 2011516410A5 JP 2010548040 A JP2010548040 A JP 2010548040A JP 2010548040 A JP2010548040 A JP 2010548040A JP 2011516410 A5 JP2011516410 A5 JP 2011516410A5
- Authority
- JP
- Japan
- Prior art keywords
- fibrosis
- modified
- compound according
- compound
- sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 206010016654 Fibrosis Diseases 0.000 claims 9
- 230000004761 fibrosis Effects 0.000 claims 9
- 229920000272 Oligonucleotide Polymers 0.000 claims 7
- 239000002777 nucleoside Substances 0.000 claims 6
- 125000003835 nucleoside group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 210000002950 fibroblast Anatomy 0.000 claims 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 206010013012 Dilatation ventricular Diseases 0.000 claims 2
- 230000027455 binding Effects 0.000 claims 2
- 230000000295 complement Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims 2
- 238000004904 shortening Methods 0.000 claims 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-Methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- 206010059512 Apoptosis Diseases 0.000 claims 1
- 229940107161 Cholesterol Drugs 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 206010019668 Hepatic fibrosis Diseases 0.000 claims 1
- 208000001083 Kidney Disease Diseases 0.000 claims 1
- 208000009856 Lung Disease Diseases 0.000 claims 1
- 208000005069 Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010050207 Skin fibrosis Diseases 0.000 claims 1
- 210000000952 Spleen Anatomy 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 229960005188 collagen Drugs 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 230000003247 decreasing Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000893 fibroproliferative Effects 0.000 claims 1
- 201000010238 heart disease Diseases 0.000 claims 1
- 230000004217 heart function Effects 0.000 claims 1
- 201000009673 liver disease Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
Claims (13)
- 対象の線維症または線維増殖性疾患を治療、予防、または診断するために使用するmiR-21またはその前駆体と相補的な核酸塩基配列を有する12〜30連結ヌクレオシドからなる修飾オリゴヌクレオチドを含む化合物。
- 線維症が、肝線維症、心線維症、腎線維症、肺線維症、皮膚線維症、加齢関連線維症、または脾線維症である請求項1記載の化合物。
- 該対象が、心疾患または病状、肝疾患または病状、肺疾患または病状、および腎疾患または病状からなる少なくとも1の疾患または病状を有する請求項1または2記載の化合物。
- 該対象に投与するための1またはそれ以上のさらなる医薬品と組み合わせた請求項1〜3のいずれかに記載の化合物。
- 該対象に対する該化合物の投与が、
a)心重量増加、左心室拡大、または短縮率障害を改善し、
b)心重量増加、左心室拡大、または短縮率障害を防ぎ、および/または
c)心機能を改善する
請求項1〜4のいずれかに記載の化合物。 - 該対象に対する該化合物の投与が、
a)線維症を改善し、
b)線維症のさらなる進行を遅くし、
c)線維症のさらなる進行を停止させ、
d)線維症を減少させ、および/または
e)コラーゲン含有量を減少させる
請求項1〜4のいずれかに記載の化合物。 - 繊維芽細胞と接触させることにより、
a)繊維芽細胞の増殖を阻害し、
b)繊維芽細胞のアポトーシスを促進し、および/または
c)Sprouty 1タンパク質の発現を増加させるために用いる
修飾オリゴヌクレオチドの核酸塩基配列がmiR-21またはその前駆体と相補的である12〜30連結ヌクレオシドからなる修飾オリゴヌクレオチドを含む化合物。 - 該修飾オリゴヌクレオチドが、15、16、17、18、19、20、21、22、23、または24結合ヌクレオシドからなり、該修飾オリゴヌクレオチドの核酸塩基配列が配列番号12の核酸塩基配列の少なくとも15、少なくとも16、少なくとも17、少なくとも18、少なくとも19、少なくとも20、少なくとも21、または少なくとも22の連続核酸塩基を含む請求項1〜7のいずれかに記載の化合物。
- 該化合物がリガンドと結合した修飾オリゴヌクレオチドを含み、該リガンドが所望によりコレステロールである請求項1〜8のいずれかに記載の化合物。
- 該少なくとも1のヌクレオシド間結合が修飾ヌクレオシド間結合であり、各ヌクレオシド間結合が修飾ヌクレオシド間結合であり、該修飾ヌクレオシド間結合が所望によりホスホロチオエート結合である請求項1〜9のいずれかに記載の化合物。
- 複数のヌクレオシドのそれぞれが修飾糖を含むか、または各ヌクレオシドが修飾糖を含み、所望により各修飾糖が独立して2'-O-メトキシエチル糖、2'-フルオロ糖、2'-O-メチル糖、または二環式糖部分から選ばれる請求項1〜10のいずれかに記載の化合物。
- 少なくとも1のヌクレオシドが修飾核酸塩基を含み、修飾核酸塩基が所望により5-メチルシトシンである請求項1〜11のいずれかに記載の化合物。
- 該修飾オリゴヌクレオチドを含む化合物が医薬組成物として製造される請求項1〜12のいずれかに記載の化合物。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3183508P | 2008-02-27 | 2008-02-27 | |
EP08003570.2 | 2008-02-27 | ||
EP20080003570 EP2096171A1 (en) | 2008-02-27 | 2008-02-27 | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
US61/031,835 | 2008-02-27 | ||
US3334008P | 2008-03-03 | 2008-03-03 | |
US61/033,340 | 2008-03-03 | ||
EPPCT/EP2009/051986 | 2009-02-19 | ||
PCT/EP2009/051986 WO2009106477A1 (en) | 2008-02-27 | 2009-02-19 | Microrna (mirna) and down-stream targets for diagnostic and therapeutic purposes |
PCT/EP2009/001590 WO2009106367A1 (en) | 2008-02-27 | 2009-02-26 | Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014246185A Division JP2015107971A (ja) | 2008-02-27 | 2014-12-04 | 診断および治療のためのミクロRNA(miRNA)および下流標的 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011516410A JP2011516410A (ja) | 2011-05-26 |
JP2011516410A5 true JP2011516410A5 (ja) | 2013-01-17 |
JP6033527B2 JP6033527B2 (ja) | 2016-11-30 |
Family
ID=39639202
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010548040A Active JP6033527B2 (ja) | 2008-02-27 | 2009-02-26 | 診断および治療のためのミクロRNA(miRNA)および下流標的 |
JP2014246185A Pending JP2015107971A (ja) | 2008-02-27 | 2014-12-04 | 診断および治療のためのミクロRNA(miRNA)および下流標的 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014246185A Pending JP2015107971A (ja) | 2008-02-27 | 2014-12-04 | 診断および治療のためのミクロRNA(miRNA)および下流標的 |
Country Status (24)
Country | Link |
---|---|
US (9) | US8236777B2 (ja) |
EP (3) | EP2096171A1 (ja) |
JP (2) | JP6033527B2 (ja) |
KR (1) | KR101697482B1 (ja) |
CN (1) | CN102027113B (ja) |
AU (1) | AU2009218704C1 (ja) |
BR (1) | BRPI0907565B1 (ja) |
CA (2) | CA2716643C (ja) |
CY (1) | CY1114426T1 (ja) |
DK (1) | DK2260101T3 (ja) |
EA (1) | EA020335B1 (ja) |
ES (1) | ES2436885T3 (ja) |
HK (1) | HK1150857A1 (ja) |
HR (1) | HRP20130766T1 (ja) |
IL (1) | IL207704A (ja) |
ME (1) | ME01600B (ja) |
MX (2) | MX2010009346A (ja) |
MY (1) | MY159454A (ja) |
NZ (1) | NZ588185A (ja) |
PL (1) | PL2260101T3 (ja) |
PT (1) | PT2260101E (ja) |
SI (1) | SI2260101T1 (ja) |
UA (1) | UA100727C2 (ja) |
WO (2) | WO2009106477A1 (ja) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2281888B1 (en) | 2004-11-12 | 2015-01-07 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2096171A1 (en) | 2008-02-27 | 2009-09-02 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
US20110190372A1 (en) * | 2009-08-07 | 2011-08-04 | New York University | Compositions and methods for treating inflammatory disorders |
CN102038959B (zh) * | 2009-10-26 | 2012-12-19 | 中国科学院上海生命科学研究院 | let-7/miR-98家族在制备治疗FAS基因相关疾病的药物中的应用 |
WO2011126842A2 (en) * | 2010-03-30 | 2011-10-13 | Regulus Therapeutics Inc. | Targeting micrornas for the treatment of cardiac disorders |
EP2580328A2 (en) | 2010-06-11 | 2013-04-17 | Cellartis AB | Micrornas for the detection and isolaton of human embryonic stem cell-derived cardiac cell types |
US8815826B2 (en) | 2010-07-23 | 2014-08-26 | Regulus Therapeutics, Inc. | Targeting microRNAs for the treatment of fibrosis |
BR112013012319A2 (pt) * | 2010-12-15 | 2019-09-24 | Miragen Therapeutics | inibidores de micro rna compreendendo nucleotídeos bloqueados |
ES2868950T3 (es) * | 2011-04-25 | 2021-10-22 | Sanofi Sa | Compuestos de microARN y métodos para modular la actividad de miR-21 |
EP4008786A3 (en) * | 2011-09-06 | 2022-08-03 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | The mirna-212/132 family as a therapeutic target |
EP2763703B1 (en) | 2011-10-06 | 2018-02-14 | Miragen Therapeutics, Inc. | Control of whole body energy homeostasis by microrna regulation |
EP2592145A1 (en) * | 2011-11-11 | 2013-05-15 | Medizinische Hochschule Hannover | Medicament for the treatment of cardiac disease |
JP2015504307A (ja) * | 2011-11-22 | 2015-02-12 | インターミューン, インコーポレイテッド | 特発性肺線維症を診断および治療する方法 |
CN104619353A (zh) * | 2011-12-13 | 2015-05-13 | 俄亥俄州国家创新基金会 | 与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移 |
JP2015518475A (ja) * | 2012-04-10 | 2015-07-02 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラルシェルシェ メディカル)Inserm(Institut National Dela Sante Etde La Recherche Medicale) | 非アルコール性脂肪性肝炎の治療方法 |
US8969317B2 (en) | 2012-04-25 | 2015-03-03 | Regulus Therapeutics Inc. | MicroRNA compounds and methods for modulating miR-21 activity |
WO2013192576A2 (en) | 2012-06-21 | 2013-12-27 | Miragen Therapeutics | Oligonucleotide-based inhibitors comprising locked nucleic acid motif |
CA2782942C (en) | 2012-07-12 | 2019-08-27 | Canadian Blood Services | Method for inducing immune tolerance using polymer-modified antigenic leukocytes |
UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
EP3019176B1 (en) | 2013-07-12 | 2020-05-06 | Canadian Blood Services | Use of acellular pro-inflammatory compositions and process for making same |
EP3060664B1 (en) | 2013-10-25 | 2021-07-07 | Sanofi | Microrna compounds and methods for modulating mir-21 activity |
WO2015086828A1 (en) * | 2013-12-12 | 2015-06-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the prevention and treatment of diabetic cardiomyopathy using mir-424/322 |
WO2016004538A1 (en) | 2014-07-10 | 2016-01-14 | Canadian Blood Services | Combination therapy of a cellular pro-tolerogenic and pro-inflammatory preparations for modulating the immune system |
US9376681B2 (en) * | 2014-09-08 | 2016-06-28 | MiRagen Therapeutics, Inc. | miR-29 mimics and uses thereof |
CN107636003A (zh) | 2015-01-20 | 2018-01-26 | 米拉根医疗股份有限公司 | miR‑92抑制剂及其用途 |
CN106924757B (zh) * | 2015-12-31 | 2020-07-24 | 中国科学院遗传与发育生物学研究所 | miR-449c-5p及其拟似物在制备治疗和预防心脏瓣膜疾病产品中的应用 |
CN107034216A (zh) * | 2016-02-04 | 2017-08-11 | 中国科学技术大学 | miRancer分子的设计与应用 |
KR101835018B1 (ko) | 2016-03-03 | 2018-03-06 | 고려대학교 산학협력단 | 엑소좀 또는 엑소좀 유래 리보핵산을 포함하는 간섬유증 예방 또는 치료용 조성물 |
US11236337B2 (en) | 2016-11-01 | 2022-02-01 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
WO2019050071A1 (ko) | 2017-09-08 | 2019-03-14 | 고려대학교 산학협력단 | 엑소좀 또는 엑소좀 유래 리보핵산을 포함하는 간섬유증 예방 또는 치료용 조성물 |
CN107858419A (zh) * | 2017-11-10 | 2018-03-30 | 青岛大学 | miRNA的应用、应用其的产品及检测方法 |
CN109498642A (zh) * | 2018-12-21 | 2019-03-22 | 复旦大学附属中山医院 | 一种柯萨奇b3病毒感染导致的心脏微血管病变的靶向治疗药物 |
US20230287413A1 (en) | 2020-04-09 | 2023-09-14 | Technische Universität München | Targeted delivery of an inhibitor of mir-21 to macrophages for the treatment of pulmonary fibrosis |
US20230302139A1 (en) * | 2020-07-31 | 2023-09-28 | University Of Florida Research Foundation, Incorporated | Targeted rna degradation allows precision repurposing of protein-targeted small molecule medicines to rna |
WO2022184888A2 (en) * | 2021-03-05 | 2022-09-09 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for use in the treatment of corneal dystrophies |
KR102549208B1 (ko) * | 2021-04-08 | 2023-06-30 | 연세대학교 산학협력단 | 심혈관 질환과 관련된 LncRNA 및 이의 용도 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050115231A (ko) * | 2003-02-10 | 2005-12-07 | 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 | 포유동물 세포의 조절 |
WO2004083430A2 (en) | 2003-03-21 | 2004-09-30 | Santaris Pharma A/S | SHORT INTERFERING RNA (siRNA) ANALOGUES |
KR20150028829A (ko) * | 2003-11-17 | 2015-03-16 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
JP5697297B2 (ja) | 2004-05-14 | 2015-04-08 | ロゼッタ ジノミクス リミテッド | マイクロnasおよびその使用 |
US20060142193A1 (en) * | 2004-11-09 | 2006-06-29 | Baylor College Of Medicine | Selective inhibition of rock1 in cardiac therapy |
US20070213292A1 (en) * | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
CA3042781C (en) | 2006-04-03 | 2021-10-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
EP2476762B1 (de) | 2006-10-09 | 2014-01-08 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) zur Diagnose und Therapie von Herzerkrankungen |
CA2671294A1 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-21 regulated genes and pathways as targets for therapeutic intervention |
WO2009058818A2 (en) | 2007-10-29 | 2009-05-07 | The Board Of Regents Of The University Of Texas System | Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling |
EP2096171A1 (en) | 2008-02-27 | 2009-09-02 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
-
2008
- 2008-02-27 EP EP20080003570 patent/EP2096171A1/en not_active Withdrawn
-
2009
- 2009-02-19 WO PCT/EP2009/051986 patent/WO2009106477A1/en active Application Filing
- 2009-02-26 CA CA2716643A patent/CA2716643C/en active Active
- 2009-02-26 PL PL09714079T patent/PL2260101T3/pl unknown
- 2009-02-26 ES ES09714079.2T patent/ES2436885T3/es active Active
- 2009-02-26 MX MX2010009346A patent/MX2010009346A/es active IP Right Grant
- 2009-02-26 JP JP2010548040A patent/JP6033527B2/ja active Active
- 2009-02-26 CA CA3123067A patent/CA3123067A1/en not_active Abandoned
- 2009-02-26 SI SI200930690T patent/SI2260101T1/sl unknown
- 2009-02-26 AU AU2009218704A patent/AU2009218704C1/en active Active
- 2009-02-26 EA EA201070992A patent/EA020335B1/ru unknown
- 2009-02-26 CN CN200980115916.9A patent/CN102027113B/zh active Active
- 2009-02-26 EP EP09714079.2A patent/EP2260101B1/en active Active
- 2009-02-26 DK DK09714079.2T patent/DK2260101T3/da active
- 2009-02-26 ME MEP-2013-93A patent/ME01600B/me unknown
- 2009-02-26 KR KR1020107021182A patent/KR101697482B1/ko active IP Right Grant
- 2009-02-26 EP EP20130160931 patent/EP2628800A1/en not_active Withdrawn
- 2009-02-26 MY MYPI2010004041A patent/MY159454A/en unknown
- 2009-02-26 UA UAA201011410A patent/UA100727C2/ru unknown
- 2009-02-26 MX MX2011012838A patent/MX336299B/es unknown
- 2009-02-26 US US12/919,592 patent/US8236777B2/en active Active
- 2009-02-26 WO PCT/EP2009/001590 patent/WO2009106367A1/en active Application Filing
- 2009-02-26 PT PT97140792T patent/PT2260101E/pt unknown
- 2009-02-26 NZ NZ588185A patent/NZ588185A/xx unknown
- 2009-02-26 BR BRPI0907565-8A patent/BRPI0907565B1/pt active IP Right Grant
-
2010
- 2010-08-19 IL IL207704A patent/IL207704A/en active IP Right Grant
-
2011
- 2011-05-17 HK HK11104841.0A patent/HK1150857A1/xx unknown
-
2012
- 2012-06-28 US US13/535,652 patent/US8592389B2/en active Active
-
2013
- 2013-08-13 CY CY20131100690T patent/CY1114426T1/el unknown
- 2013-08-13 HR HRP20130766AT patent/HRP20130766T1/hr unknown
- 2013-10-23 US US14/061,350 patent/US9220722B2/en active Active
-
2014
- 2014-12-04 JP JP2014246185A patent/JP2015107971A/ja active Pending
-
2015
- 2015-11-20 US US14/947,291 patent/US9663788B2/en active Active
-
2017
- 2017-04-19 US US15/491,633 patent/US10028974B2/en active Active
-
2018
- 2018-06-22 US US16/015,495 patent/US10434117B2/en active Active
-
2019
- 2019-08-16 US US16/542,985 patent/US20200069720A1/en not_active Abandoned
-
2020
- 2020-09-01 US US17/008,782 patent/US20210113603A1/en not_active Abandoned
-
2022
- 2022-06-22 US US17/846,518 patent/US20230028937A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011516410A5 (ja) | ||
JP2012050438A5 (ja) | ||
JP2012050439A5 (ja) | ||
JP2011501962A5 (ja) | ||
JP2014511686A5 (ja) | ||
JP2010505432A5 (ja) | ||
JP2012029693A5 (ja) | ||
HRP20130766T1 (hr) | Mikrornk (mirnk) mir-21 za dijagnostiäśke i terapijske svrhe | |
JP2009506124A5 (ja) | ||
JP2017536119A5 (ja) | ||
JP2010530239A5 (ja) | ||
JP2006141402A5 (ja) | ||
JP2007533742A5 (ja) | 癌治療のためのスルビビンオリゴヌクレオチドおよびゲムシタビンを含む組成物 | |
JP2014530004A5 (ja) | ||
JP2008514223A5 (ja) | ||
JP2013518605A5 (ja) | ||
JP2012508560A5 (ja) | ||
US8871731B2 (en) | Micro-RNA for the regulation of cardiac apoptosis and contractile function | |
JP2009508527A5 (ja) | ||
JP2016116520A5 (ja) | ||
JP2018530529A5 (ja) | ||
JP2019088329A5 (ja) | ||
JP2014513954A5 (ja) | ||
JP2013226147A5 (ja) | ||
JP2018525030A5 (ja) |